Research Overview
· Last Reviewed May 3, 2026· PSI Editorial Board· IndependentCan Peptides Help With Obesity-Related Metabolic Disease?
The honest map across 8 obesity scenarios — what is FDA-approved, where bariatric surgery rules, and how comprehensive care fits.
WHICH OBESITY CONTEXT?
Obesity Context
Animal Studies
Human Trials
Adults BMI 30+ wanting maximum weight reduction
FDA-approved Zepbound chronic weight management
Adults BMI 30+ with cardiovascular risk
FDA-approved Wegovy chronic weight management
Adults BMI 27+ with weight-related comorbidity
FDA-approved chronic weight management
Adolescents 12 years and older with obesity
FDA-approved Wegovy + Saxenda pediatric
BMI 35+ considering bariatric surgery
validated ASMBS framework
Obesity with rare genetic syndrome
FDA-approved Setmelanotide indication
Obesity wanting non-peptide pharmacotherapy
FDA-approved phentermine/Contrave/Qsymia/orlistat
Phase 3 triple-agonist research access
investigational class context
How counts are scaled → · Tap any row to see the studies →
Quick Answer
Obesity has well-characterized validated approaches in clinical practice. Foundations include comprehensive evaluation by primary care, endocrinology, weight medicine, or obesity medicine specialty. Workup covers BMI, waist circumference, blood pressure, lipid panel, fasting glucose, HbA1c, and metabolic panel. Additional assessment includes complication screening for T2D, MASLD, sleep apnea, and cardiovascular disease.
Lifestyle intervention is foundational across all obesity care. Mediterranean dietary pattern provides substantial cardiometabolic outcomes evidence. Physical activity and behavioral intervention support sustained weight management.
Tirzepatide is FDA-approved as Zepbound for chronic weight management. SURMOUNT-1 trial demonstrated approximately 21 percent weight reduction at 72 weeks. SURMOUNT-5 demonstrated superior weight reduction versus Wegovy.
Semaglutide is FDA-approved as Wegovy for chronic weight management. STEP-1 trial demonstrated approximately 15 percent weight reduction at 68 weeks. SELECT trial demonstrated 20 percent reduction in major cardiovascular events.
Liraglutide is FDA-approved as Saxenda for chronic weight management. The compound is approved for adults and adolescents 12 years and older.
Retatrutide is investigational with Phase 3 TRIUMPH-1 program at Eli Lilly. The compound is a triple GLP-1/GIP/glucagon receptor agonist with Phase 2 evidence approximately 24 percent at 48 weeks.
The honest framing: three peptides hold FDA approvals for chronic weight management with substantial Phase 3 evidence. Bariatric surgery is validated for eligible patients per ASMBS guidelines. For broader context, see Peptides for Metabolic Health, Peptides for Weight Loss, and Peptides for Belly Fat.
Tirzepatide SURMOUNT-5 vs Semaglutide for chronic weight management
Head-to-head Phase 3 evidence in obesity
Tirzepatide is FDA-approved as Zepbound for chronic weight management with substantial Phase 3 evidence. SURMOUNT-1 demonstrated approximately 21 percent weight reduction at 72 weeks in adults with obesity without diabetes. Mechanism is dual GIP/GLP-1 receptor agonism with potential for additive metabolic effects. Once-weekly subcutaneous dosing offers convenient administration with dose titration over 20 weeks. The compound demonstrates the greatest weight reduction in the GLP-1 RA class.
Semaglutide is FDA-approved as Wegovy for chronic weight management with substantial Phase 3 evidence. STEP-1 demonstrated approximately 15 percent weight reduction at 68 weeks. Mechanism is GLP-1 receptor agonism with glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central appetite reduction. Once-weekly subcutaneous dosing matches Tirzepatide convenience. SELECT trial established cardiovascular outcomes benefits in established CV disease.
PSI's reading: SURMOUNT-5 head-to-head Phase 3 trial demonstrated Tirzepatide superior weight reduction versus Wegovy in adults with obesity without diabetes. Tirzepatide produces greater weight reduction. Semaglutide has earlier cardiovascular outcomes evidence (SELECT). Patient selection considers individualized factors, cardiovascular risk, formulation preference, and access under primary care, endocrinology, or weight medicine specialty guidance per AACE/TOS/ACC obesity algorithm. Both are appropriate validated options.
Pharmacotherapy vs bariatric surgery for obesity
FDA-approved medications versus validated surgical options
Pharmacotherapy options for obesity include FDA-approved peptide and non-peptide compounds. Peptide options include Wegovy, Zepbound, and Saxenda for chronic weight management with Phase 3 evidence. Non-peptide options include phentermine (short-term), naltrexone-bupropion (Contrave), phentermine-topiramate (Qsymia), orlistat (Xenical, Alli), and Setmelanotide (Imcivree) for rare genetic obesity syndromes. Pharmacotherapy is appropriate for adults with BMI 30 or higher, or BMI 27 or higher with weight-related comorbidity per AACE/TOS/ACC.
Bariatric surgery is validated for eligible patients with BMI 35 or higher per current ASMBS guidelines. Roux-en-Y gastric bypass, sleeve gastrectomy, and adjustable gastric banding are validated procedures. Bariatric surgery demonstrates substantial weight reduction (typically 25 to 35 percent), substantial T2D remission rates, and improvements across metabolic complications. ASMBS expanded indications consider BMI 30 or higher with metabolic disease in select populations. Surgical and metabolic specialty coordination is essential.
PSI's reading: pharmacotherapy and bariatric surgery hold complementary FDA-approved positioning in comprehensive obesity care. Pharmacotherapy is appropriate first-line for many patients with BMI 30+ or 27+ with comorbidity. Bariatric surgery is validated for eligible higher-BMI patients per ASMBS. Combination of pharmacotherapy and surgery is increasingly common in clinical practice. Specialty coordination including primary care, weight medicine, obesity medicine, endocrinology, and bariatric surgery ensures appropriate matching.
GLP-1 RA peptides vs non-peptide obesity pharmacotherapy
Multiple FDA-approved classes for chronic weight management
GLP-1 receptor agonist peptides hold substantial Phase 3 evidence for chronic weight management. Wegovy demonstrates approximately 15 percent weight reduction. Zepbound demonstrates approximately 21 percent weight reduction with SURMOUNT-5 superior to Wegovy. Saxenda demonstrates approximately 8 percent weight reduction with adolescent indication. Cardiovascular outcomes benefits are established for select compounds. The class typically achieves greatest weight reduction in modern obesity pharmacotherapy.
Non-peptide FDA-approved obesity pharmacotherapy includes multiple validated options. Phentermine is FDA-approved short-term (typically 12 weeks). Naltrexone-bupropion (Contrave) is FDA-approved chronic weight management with mechanism affecting reward and appetite pathways. Phentermine-topiramate (Qsymia) is FDA-approved chronic weight management. Orlistat (Xenical, Alli) is FDA-approved with intestinal lipase inhibition mechanism. Setmelanotide (Imcivree) is FDA-approved for rare genetic obesity syndromes (POMC, LEPR, PCSK1 deficiency, BBS).
PSI's reading: multiple FDA-approved obesity pharmacotherapy options exist with different mechanisms, efficacy, and patient populations. GLP-1 RA peptides typically achieve greatest weight reduction in modern obesity care. Non-peptide options are appropriate alternatives based on individualized factors including cost, access, comorbidities, and side-effect tolerability. Specialty guidance ensures appropriate matching per AACE/TOS/ACC obesity algorithm.
Comprehensive obesity care vs single-modality approach
Lifestyle plus pharmacotherapy plus surgery versus partial intervention
Obesity is a chronic relapsing disease per AMA recognition (2013) and major medical society guidelines. Comprehensive obesity care addresses multiple validated modalities. Lifestyle intervention provides foundational weight management with Mediterranean dietary pattern, physical activity 150 minutes weekly, behavioral intervention, sleep optimization, and stress management. Pharmacotherapy is FDA-approved for adults meeting BMI criteria. Bariatric surgery is validated for eligible higher-BMI patients per ASMBS guidelines.
Single-modality approaches address only specific elements. Lifestyle alone has been demonstrated to produce approximately 5 to 10 percent weight reduction with sustained intervention. Pharmacotherapy alone produces variable weight reduction by class. Bariatric surgery alone produces substantial weight reduction but requires coordinated metabolic and lifestyle support. Comprehensive approach combining modalities produces greatest sustained outcomes per validated frameworks.
PSI's reading: comprehensive obesity care including lifestyle, pharmacotherapy, and bariatric surgery for eligible patients dominates evidence-graded medicine. Single-compound peptide approach without comprehensive evaluation bypasses essential lifestyle foundation and complication management. Specialty coordination including primary care, weight medicine, obesity medicine, endocrinology, cardiology, hepatology, and bariatric surgery ensures comprehensive multi-modality approach per AACE/TOS/ACC and ASMBS guidelines.
The Compounds, Ranked by Evidence
Ordered by strength of controlled human data, not popularity.
Of the 4 peptides discussed for obesity-related metabolic disease, three hold FDA approvals for chronic weight management with substantial Phase 3 evidence. Semaglutide (Wegovy), Tirzepatide (Zepbound), and Liraglutide (Saxenda) are FDA-approved. Pediatric indications exist for Wegovy and Saxenda for adolescents 12 years and older. Retatrutide is in Phase 3 TRIUMPH-1 development at Eli Lilly. Validated comprehensive obesity care including lifestyle intervention, FDA-approved pharmacotherapy (peptide and non-peptide options), bariatric surgery for eligible patients, and metabolic complication management under primary care, endocrinology, weight medicine, or obesity medicine specialty guidance dominates evidence-graded care per AACE/TOS/ACC obesity algorithm and ASMBS bariatric surgery guidelines.
Tirzepatide
FDA-approved Zepbound for chronic weight management. SURMOUNT-1 weight reduction approximately 21 percent and SURMOUNT-5 superior to Wegovy.
Counts are PubMed-indexed papers and registered clinical trials. Scale: Strong 10+, Moderate 4–9, Limited 1–3, None 0. Methodology →
| Context | Animal Studies | Human Trials |
|---|---|---|
Chronic weight management FDA-approved Zepbound | 6 Dual incretin signaling effects on weight in animal models. | 8 SURMOUNT-1 demonstrated approximately 21 percent weight reduction at 72 weeks. Jastreboff 2022 |
Head-to-head efficacy SURMOUNT-5 vs Wegovy | 4 Comparative dual vs single-receptor effects. | 4 SURMOUNT-5 demonstrated superior weight reduction versus semaglutide. Aronne 2024 |
Semaglutide
FDA-approved Wegovy for adults and adolescents 12 years and older. STEP-1 weight reduction and SELECT 20 percent CV event reduction.
| Context | Animal Studies | Human Trials |
|---|---|---|
Chronic weight management FDA-approved Wegovy | 6 Central appetite suppression effects in animal models. | 8 STEP-1 demonstrated approximately 15 percent weight reduction at 68 weeks. Wilding 2021 |
Cardiovascular outcomes FDA-approved CV indication | 4 Cardiovascular protective effects in animal models. | 6 SELECT demonstrated 20 percent reduction in MACE. Lincoff 2023 |
Liraglutide
FDA-approved Saxenda for adults and adolescents 12 years and older. SCALE program evidence and SCALE Teen pediatric trial.
| Context | Animal Studies | Human Trials |
|---|---|---|
Adult chronic weight management FDA-approved Saxenda | 6 GLP-1 signaling effects on weight in animal models. | 6 SCALE program demonstrated approximately 8 percent weight reduction at 56 weeks. Pi-Sunyer 2015 |
Adolescent obesity (12 years and older) FDA-approved pediatric | 2 Pediatric-relevant pharmacology data. | 2 SCALE Teen trial supported the adolescent indication. Kelly 2020 |
Retatrutide
Investigational; Phase 3 TRIUMPH-1 program at Eli Lilly. Triple GLP-1/GIP/glucagon agonist with Phase 2 weight reduction approximately 24 percent. Not FDA-approved.
| Context | Animal Studies | Human Trials |
|---|---|---|
Obesity weight management Phase 3 TRIUMPH-1 ongoing | 6 Triple incretin signaling evidence in obesity animal models. | 4 Phase 2 demonstrated approximately 24 percent weight reduction at 48 weeks. Jastreboff 2023 |
What's Marketed vs What's Studied
7 common claims, corrected.
“Obesity is purely a willpower issue rather than a medical condition.”
Obesity is recognized as a chronic relapsing metabolic disease by the American Medical Association (2013) and major medical society guidelines including AACE/TOS/ACC. The condition involves complex interactions of genetics, environment, neurohormonal regulation, and behavior. Comprehensive medical evaluation and validated multi-modality care including lifestyle, pharmacotherapy, and bariatric surgery are appropriate per evidence-graded guidelines.
“Compounded GLP-1 receptor agonists are equivalent to FDA-approved Wegovy and Zepbound.”
FDA-approved Wegovy and Zepbound have substantial Phase 3 evidence with quality control and regulatory oversight. Compounded peptides outside FDA-approved framework lack equivalent evidence and quality assurance. Clinical practice relies on FDA-approved products under specialty guidance per AACE/TOS/ACC obesity algorithm.
“Bariatric surgery is only for severe obesity.”
Bariatric surgery is validated for eligible patients with BMI 35 or higher per current ASMBS guidelines. ASMBS expanded indications also support consideration of BMI 30 or higher with metabolic disease in select populations. Roux-en-Y gastric bypass, sleeve gastrectomy, and adjustable gastric banding are validated procedures. Bariatric surgery demonstrates substantial weight reduction and metabolic improvements.
“Obesity pharmacotherapy is only for short-term use.”
Obesity is a chronic disease requiring chronic management. FDA-approved chronic weight management therapies including Wegovy, Zepbound, Saxenda, Contrave, Qsymia, and orlistat are designed for long-term use in patients meeting indications. Phentermine is FDA-approved for short-term use (typically 12 weeks). Discontinuation is associated with weight regain in most patients per Phase 3 trial extension data.
“GLP-1 receptor agonists are only for adults.”
Wegovy (Semaglutide) and Saxenda (Liraglutide) are FDA-approved for adolescents 12 years and older with obesity. ELLIPSE pediatric T2D trial supported Liraglutide pediatric T2D indication. Pediatric obesity management requires pediatric endocrinology coordination with comprehensive lifestyle, family-based behavioral intervention, and pharmacotherapy when indicated per AAP childhood obesity guideline.
“Setmelanotide (Imcivree) is for general obesity.”
Setmelanotide (Imcivree) is FDA-approved specifically for rare genetic obesity syndromes including POMC deficiency, LEPR deficiency, PCSK1 deficiency, and Bardet-Biedl syndrome (BBS). The compound activates MC4 receptor signaling. The compound is not appropriate for general obesity. Validated general obesity pharmacotherapy includes Wegovy, Zepbound, Saxenda, and non-peptide FDA-approved options.
“I can self-treat obesity with peptides without medical supervision.”
Comprehensive evaluation by primary care, endocrinology, weight medicine, or obesity medicine specialty identifies contributing factors and matches treatment per AACE/TOS/ACC obesity algorithm. Workup includes BMI, waist circumference, lipid panel, fasting glucose, HbA1c, blood pressure, and complication screening. Self-treatment bypasses essential clinical assessment and validated framework.
If Considering Use, Here Is How to Be Safe
How to evaluate sources, verify quality, and find qualified physicians.
Get comprehensive obesity evaluation.
BMI, waist circumference, lipid panel, fasting glucose, HbA1c, blood pressure, and complication screening guide treatment decisions per AACE/TOS/ACC obesity algorithm.
Establish primary care, endocrinology, weight medicine, or obesity medicine.
Specialty evaluation determines appropriate therapy matching. Bariatric surgery requires surgical coordination. Pediatric endocrinology manages adolescent obesity.
Match validated approaches to your situation.
Lifestyle foundational. Pharmacotherapy for BMI 30+ or 27+ with comorbidity. Bariatric surgery for BMI 35+ per ASMBS. Specialty guidance ensures matching.
Optimize lifestyle and validated foundations.
Mediterranean dietary pattern, physical activity 150 minutes weekly, resistance training, behavioral intervention, adequate sleep, stress management, smoking cessation, and limited alcohol form the validated foundation.
Approach compounded peptides cautiously.
FDA-approved Wegovy, Zepbound, and Saxenda have substantial Phase 3 evidence. Compounded peptides outside FDA-approved framework are not validated practice.
Address comorbidities and complications when present.
T2D, MASLD, sleep apnea, cardiovascular disease, PCOS, and orthopedic concerns commonly accompany obesity. Comprehensive specialty coordination ensures multi-modality approach.
The regulatory landscape for obesity peptides is rapidly evolving. Wegovy and Zepbound approvals continue to drive major commercial adoption. SURMOUNT-5 demonstrated Tirzepatide superior to Wegovy. SELECT trial established Semaglutide cardiovascular outcomes in overweight or obesity without diabetes. Wegovy adolescent indication and SURMOUNT-OSA sleep apnea benefits have expanded indications. Retatrutide Phase 3 TRIUMPH-1 program at Eli Lilly is ongoing. Compounded GLP-1 receptor agonists have faced regulatory scrutiny during commercial supply normalization. PSI tracks these developments and updates this page as material changes occur.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Common Questions
Are any peptides FDA-approved for obesity?
Yes. Three peptides hold FDA approvals for chronic weight management. Semaglutide is FDA-approved as Wegovy for adults and adolescents 12 years and older. Tirzepatide is FDA-approved as Zepbound for adults. Liraglutide is FDA-approved as Saxenda for adults and adolescents 12 years and older. Retatrutide is investigational with Phase 3 TRIUMPH-1 program at Eli Lilly. Pharmacotherapy is FDA-approved for adults with BMI 30 or higher, or BMI 27 or higher with weight-related comorbidity per AACE/TOS/ACC.
Should I see an endocrinologist or weight medicine specialist?
Primary care typically manages initial obesity evaluation and routine management for many patients. Endocrinology specialty manages complex metabolic disease and complications. Weight medicine specialty and obesity medicine specialty provide comprehensive obesity care including pharmacotherapy and lifestyle programs. Bariatric surgery requires bariatric surgery specialty coordination. Pediatric endocrinology manages adolescent obesity. AACE/TOS/ACC obesity algorithm provides framework for specialty coordination.
What is the comprehensive evaluation for obesity?
Comprehensive obesity evaluation per AACE/TOS/ACC algorithm includes BMI, waist circumference, blood pressure, lipid panel (total cholesterol, LDL, HDL, triglycerides), fasting plasma glucose, HbA1c, metabolic panel, liver function tests, urine microalbumin, and cardiovascular risk assessment. Complication screening includes T2D evaluation, MASLD assessment, sleep apnea screening, PCOS evaluation, and orthopedic considerations. Annual monitoring is appropriate during management.
How do GLP-1 receptor agonists work for obesity?
GLP-1 receptor agonists are synthetic peptides resistant to DPP-4 degradation that activate GLP-1 receptors. Mechanism in obesity contexts is primarily central appetite reduction through hypothalamic regulation, gastric emptying delay producing earlier satiety, and metabolic effects. Weight reduction develops progressively over 56 to 72 weeks in Phase 3 trials. The class typically achieves greatest weight reduction in modern obesity pharmacotherapy. Cardiovascular outcomes benefits are established for select compounds.
What is the difference between Wegovy and Zepbound?
Both compounds are FDA-approved for chronic weight management with substantial Phase 3 evidence. Wegovy (Semaglutide) is a GLP-1 receptor agonist (single receptor) approved by Novo Nordisk. Zepbound (Tirzepatide) is a dual GIP/GLP-1 receptor agonist approved by Eli Lilly. SURMOUNT-5 head-to-head trial demonstrated Zepbound superior weight reduction versus Wegovy. Wegovy has earlier cardiovascular outcomes evidence (SELECT) and adolescent indication. Patient selection considers individualized factors under specialty guidance.
What about non-peptide obesity medications?
Multiple non-peptide FDA-approved obesity pharmacotherapy options exist. Phentermine is FDA-approved short-term (typically 12 weeks). Naltrexone-bupropion (Contrave) is FDA-approved chronic weight management. Phentermine-topiramate (Qsymia) is FDA-approved chronic weight management. Orlistat (Xenical, Alli) is FDA-approved with intestinal lipase inhibition mechanism. Setmelanotide (Imcivree) is FDA-approved for rare genetic obesity syndromes. Specialty guidance per AACE/TOS/ACC algorithm matches options to individualized factors.
What about bariatric surgery for obesity?
Bariatric surgery is validated for eligible patients with BMI 35 or higher per current ASMBS guidelines. Roux-en-Y gastric bypass, sleeve gastrectomy, and adjustable gastric banding are validated procedures. Bariatric surgery demonstrates substantial weight reduction (typically 25 to 35 percent), substantial T2D remission rates, and improvements across metabolic complications. ASMBS expanded indications also support BMI 30 or higher with metabolic disease in select populations. Surgical and metabolic specialty coordination is essential.
What are the side effects of GLP-1 receptor agonists for obesity?
Common GLP-1 receptor agonist side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, and reduced appetite. GI symptoms are most common during dose titration. Less common effects include pancreatitis (boxed warning), gallbladder disease, and rare thyroid C-cell tumors in animal models. Contraindications include personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Pregnancy and certain GI conditions affect prescribing.
Can adolescents use GLP-1 receptor agonists for obesity?
Yes. Wegovy (Semaglutide) and Saxenda (Liraglutide) are FDA-approved for adolescents 12 years and older with obesity. SCALE Teen trial supported Saxenda pediatric indication. Adolescent obesity management requires pediatric endocrinology specialty coordination, growth assessment, pubertal staging evaluation, family-based behavioral intervention, and cardiovascular risk evaluation per AAP childhood obesity guideline. Other GLP-1 RAs are not FDA-approved for pediatric obesity.
What about MASLD and obesity?
Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) is closely associated with obesity. Approximately 25 percent of US adults have MASLD. Comprehensive evaluation includes liver function tests, liver imaging, and FibroScan or liver biopsy when appropriate. Resmetirom (Rezdiffra) was FDA-approved in 2024 for MASH with moderate to advanced fibrosis. Lifestyle and weight management form the foundation. Semaglutide ESSENCE Phase 3 trial program studies MASLD applications.
What about obstructive sleep apnea and obesity?
Obstructive sleep apnea is closely associated with obesity. Untreated sleep apnea contributes to insulin resistance, cardiovascular disease, and weight gain. Sleep study diagnosis is appropriate when symptoms suggest sleep apnea. Continuous positive airway pressure (CPAP) is validated treatment. SURMOUNT-OSA trial demonstrated Tirzepatide benefits in obesity with obstructive sleep apnea. Pulmonology and sleep medicine coordination ensures appropriate evaluation and management.
Are these peptides legal in the United States?
Semaglutide is FDA-approved as Wegovy by Novo Nordisk by prescription. Tirzepatide is FDA-approved as Zepbound by Eli Lilly by prescription. Liraglutide is FDA-approved as Saxenda by Novo Nordisk by prescription. Retatrutide is investigational; access is through clinical trial enrollment. Compounded GLP-1 receptor agonists are available through 503A pharmacies during commercial supply shortages but represent non-validated practice for indications outside FDA-approved scope. Always work with a licensed prescriber within validated medical framework.
How long does it take for GLP-1 receptor agonists to work for weight loss?
Weight loss develops progressively over months. STEP-1 demonstrated approximately 15 percent weight reduction at 68 weeks with Wegovy. SURMOUNT-1 demonstrated approximately 21 percent weight reduction at 72 weeks with Zepbound. SCALE Obesity and Prediabetes demonstrated approximately 8 percent weight reduction at 56 weeks with Saxenda. Dose titration over 16 to 20 weeks is standard to manage GI side effects. Sustained intervention is required for sustained outcomes per Phase 3 trial extension data. Comprehensive monitoring under specialty guidance ensures appropriate progress assessment.
What happens when I stop GLP-1 receptor agonist therapy?
Weight regain is common after discontinuation per Phase 3 trial extension data. STEP-4 and SURMOUNT-4 trials demonstrated substantial weight regain after discontinuation despite continued lifestyle intervention. Obesity is a chronic relapsing disease requiring chronic management per AACE/TOS/ACC. Sustained pharmacotherapy is appropriate for many patients. Discontinuation should be discussed with prescriber and may include consideration of alternative pharmacotherapy or bariatric surgery.
Should lifestyle intervention be addressed alongside peptide therapy?
Yes. Comprehensive lifestyle intervention remains foundational alongside any pharmacotherapy. Mediterranean dietary pattern provides substantial cardiometabolic outcomes evidence. Physical activity 150 minutes moderate intensity weekly improves multiple metabolic factors. Resistance training 2 to 3 sessions weekly preserves muscle mass during weight loss. Adequate sleep, stress management, smoking cessation, and limited alcohol form the validated foundation. Specialty guidance integrates lifestyle and pharmacotherapy.
What questions should I ask my doctor about peptides for obesity?
Ask: (1) What is my comprehensive evaluation including BMI, waist circumference, lipid panel, fasting glucose, HbA1c, and complication screening? (2) Do I meet FDA-approved indications for chronic weight management (BMI 30+ or 27+ with comorbidity)? (3) For my situation, do peptide options apply (Wegovy, Zepbound, Saxenda)? (4) Are non-peptide options (Contrave, Qsymia, orlistat) appropriate alternatives? (5) Should bariatric surgery be considered (BMI 35+ per ASMBS)? (6) How do contraindications apply (medullary thyroid carcinoma history, pancreatitis history, pregnancy planning)? (7) What is my realistic timeline and monitoring plan?
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.